Product
ACALABRUTINIB
1 clinical trial
15 indications
Indication
Aggressive B-cell LymphomasIndication
B-Cell Non-Hodgkin LymphomaIndication
Aggressive B-cell Non-Hodgkin LymphomaIndication
Diffuse Large B-cell LymphomaIndication
Indolent B-cell LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Noonan syndromeIndication
EBV-Positive DLBCLIndication
NOSIndication
High-Grade B-Cell LymphomaIndication
Follicular LymphomaClinical trial
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell LymphomasStatus: Recruiting, Estimated PCD: 2025-03-01